Active Ingredient History
Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor. Development of galunisertib by Eli Lilly was discontinued in January 2020. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 1)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 1/Phase 2)
Healthy Volunteers (Phase 1)
Myelodysplastic Syndromes (Phase 2/Phase 3)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasm Metastasis (Phase 1/Phase 2)
Neoplasms (Phase 1/Phase 2)
Ovarian Diseases (Phase 1)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue